NCT03673176View on ClinicalTrials.gov

Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 11, 2013

Primary Completion Date

August 2, 2021

Study Completion Date

August 2, 2021

Conditions
Emphysema
Interventions
RADIATION

Stereotactic Ablative Radiotherapy (SABR)

The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.

Trial Locations (1)

94305

Stanford Cancer Center, Palo Alto

All Listed Sponsors
collaborator

Varian, a Siemens Healthineers Company

INDUSTRY

lead

Stanford University

OTHER

NCT03673176 - Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy | Biotech Hunter | Biotech Hunter